

# VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100**

## Overview

<b>2024/04/26 19:30:43</b>	
<b>Price</b>	<b>373.20 EUR</b>
<b>Difference</b>	<span style="color: green;">▲</span> <b>0.62% (2.30)</b>

<b>General attributes</b>	
<b>ISIN</b>	US92532F1003
<b>Symbol</b>	VRTX
<b>Exchange</b>	Duesseldorf
<b>Currency</b>	EUR
<b>Sector</b>	Chemical / Pharmaceutical / Health
<b>Security type</b>	Stock
<b>Market cap (m)</b>	96,025 EUR
<b>Benchmark</b>	S&P 500

<b>Market data</b>	
<b>Bid (Bid size)</b>	-
<b>Ask (Ask size)</b>	-
<b>Open</b>	371.75 EUR
<b>High</b>	373.20 EUR
<b>Low</b>	368.25 EUR
<b>Close (prev. day)</b>	370.90 EUR
<b>VWAP</b>	-
<b>Volume (pcs)</b>	0
<b>Trading volume</b>	0.00
<b>Number of trades</b>	7
<b>Last size</b>	0

<b>Futures and Options</b>	
<b>Related Futures</b>	-
<b>Related Options</b>	-

<b>PDF Downloads</b>	
Company report: VERTEX PHARMACEUTICALS INC.	<a href="#">↓</a>



Information about previous performance does not guarantee future performance.  
**Source:** FactSet

### Recent research

on instrument		on sector		on market	
Date			Headline		Download
2024/04/26			Global Equity Ratings		<a href="#">↓</a>
2024/04/03			Global Equity Ratings		<a href="#">↓</a>
2024/03/13			Global Equity Ratings		<a href="#">↓</a>
2024/02/22			Global Equity Ratings		<a href="#">↓</a>
2024/02/14			Global Equity Ratings		<a href="#">↓</a>

## Details

2024/04/26 19:30:43

**Price**

373.20 EUR

**Difference** ▲ 0.62% (2.30)

**General attributes**

ISIN	US92532F1003
Symbol	VRTX
Exchange	Duesseldorf
Currency	EUR
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	96,025 EUR
Benchmark	S&P 500

**Market data**

Bid (Bid size)	-
Ask (Ask size)	-
Open	371.75 EUR
High	373.20 EUR
Low	368.25 EUR
Close (prev. day)	370.90 EUR
VWAP	-
Volume (pcs)	0
Trading volume	0.00
Number of trades	7
Last size	0

**Performance and Risk**

	6m	1Y	3Y
Perf (%)	+9.11%	+28.14%	+107.82%
Perf (abs.)	+31.15	+81.95	+193.62
Beta	0.76	0.69	0.60
Volatility	25.91	21.89	26.06

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

**Price data**

Ø price 5 days   Ø volume 5 days (pcs.)	374.84 EUR (0)
Ø price 30 days   Ø volume 30 days (pcs.)	376.39 EUR (0)
Ø price 100 days   Ø volume 100 days (pcs.)	379.35 EUR (2)
Ø price 250 days   Ø volume 250 days (pcs.)	346.24 EUR (1)
YTD High   date	410.90 EUR (2024/01/30)
YTD Low   date	361.65 EUR (2024/04/11)
52 Weeks High   date	410.90 EUR (2024/01/30)
52 Weeks Low   date	290.00 EUR (2023/04/27)

**All listings for VERTEX PHARMACEUTICALS INC.**

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/04/26	17:35	372.55 EUR	0.02	9
Vienna Stock Exchange	2024/04/26	17:32	372.90 EUR	0.00	2
Tradegate	2024/04/26	22:26	371.40 EUR	0.07	15
Stuttgart	2024/04/26	19:57	373.10 EUR	0.00	4
Nasdaq	2024/	22:00	397.48 USD	271.32	21,542

	04/26					
Munich	2024/ 04/26	08:00	370.50	EUR	0.00	2
London Stock Exchange	2024/ 04/26	15:54	395.17	USD	0.01	12
Hanover	2024/ 04/26	08:05	370.75	EUR	0.00	3
Hamburg	2024/ 04/26	08:00	370.75	EUR	0.00	3
Frankfurt	2024/ 04/26	08:01	371.80	EUR	0.00	2
Euronext Milan MTF Trading After Hours	2024/ 02/28	19:24	393.60	EUR	0.00	1
Euronext Milan MTF Global Equity Market	2024/ 04/26	17:44	371.90	EUR	0.00	3
Duesseldorf	2024/ 04/26	19:30	373.20	EUR	0.00	7
Berlin	2024/ 04/26	08:08	370.80	EUR	0.00	2

## Company profile

### Company Logo



### Contact Details

VERTEX PHARMACEUTICALS INC.

--

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: [mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

### PDF Downloads

Company report: VERTEX  
PHARMACEUTICALS INC.



### Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

### Members of Management Board

Jeffrey Leiden Chairman of Board of Directors

Alan Garber Member of Board of Directors

Sangeeta Bhatia Member of Board of Directors

Bruce Sachs Member of Board of Directors

Diana McKenzie Member of Board of Directors

Lloyd Carney Member of Board of Directors

Michel Lagarde Member of Board of Directors

Nancy Thornberry Member of Board of Directors

Suketu Upadhyay Member of Board of Directors

Terrence Kearney Member of Board of Directors

Reshma Kewalramani Chairman of Managing Board

David Altshuler Member of Executive Committee

Amit K. Sachdev Member of Executive Committee

Bastiano Sanna Member of Executive Committee

Carmen Bozic Member of Executive Committee

Charles F. Wagner Member of Executive Committee

E. Morrey Atkinson Member of Executive Committee

Jonathan Biller Member of Executive Committee

Nia Tatsis Member of Executive Committee

Stuart A. Arbuckle Member of Executive Committee

